Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Colinz Laboratories Ltd

COLINZ

Colinz Laboratories Ltd

COLINZ
Health CarePharmaceuticals
SmallcapWith a market cap of ₹15 cr, stock is ranked 4,230
High RiskStock is 4.53x as volatile as Nifty
66.960.84% (+0.56)
66.960.84% (+0.56)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹15 cr, stock is ranked 4,230
High RiskStock is 4.53x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹15 cr, stock is ranked 4,230
High RiskStock is 4.53x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.521.78—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Colinz Laboratories Ltd is engaged in the manufacturing and marketing of pharmaceutical formulations.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -1.06%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 34.82%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue8.208.147.937.717.666.357.147.327.317.25
Raw Materialssubtract3.092.882.602.732.621.721.972.332.236.35
Power & Fuel Costsubtract0.080.080.080.100.090.080.080.110.11
Employee Costsubtract2.862.913.153.073.252.392.772.902.79
Selling & Administrative Expensessubtract1.121.531.221.161.080.961.031.081.10
Operating & Other expensessubtract0.500.240.420.180.190.680.540.130.25
Depreciation/Amortizationsubtract0.280.270.220.220.190.190.200.130.130.12
Interest & Other Itemssubtract0.120.120.080.100.070.090.080.050.040.04
Taxes & Other Itemssubtract0.06-0.03-0.080.040.050.040.140.140.170.20
EPS0.250.400.680.310.340.490.721.271.952.14
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Colinz Laboratories Ltd32.531.78—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare COLINZ with any stock or ETF
Compare COLINZ with any stock or ETF
COLINZ
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.45%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding65.92%0.00%0.00%0.00%34.08%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

COLINZ has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Colinz Laboratories standalone net profit rises 33.33% in the September 2024 quarter

Net profit of Colinz Laboratories rose 33.33% to Rs 0.16 crore in the quarter ended September 2024 as against Rs 0.12 crore during the previous quarter ended September 2023. Sales rose 3.91% to Rs 1.86 crore in the quarter ended September 2024 as against Rs 1.79 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1.861.79 4 OPM %9.146.70 - PBDT0.240.19 26 PBT0.210.16 31 NP0.160.12 33 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Colinz Laboratories to table results

Colinz Laboratories will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Colinz Laboratories to hold AGM

Colinz Laboratories announced that the 38th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Colinz Laboratories announces board meeting date

Colinz Laboratories will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Colinz Laboratories standalone net profit rises 16.67% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Colinz Laboratories standalone net profit rises 16.67% in the June 2024 quarter

Net profit of Colinz Laboratories rose 16.67% to Rs 0.14 crore in the quarter ended June 2024 as against Rs 0.12 crore during the previous quarter ended June 2023. Sales declined 7.89% to Rs 1.75 crore in the quarter ended June 2024 as against Rs 1.90 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1.751.90 -8 OPM %9.147.89 - PBDT0.220.18 22 PBT0.190.15 27 NP0.140.12 17 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Colinz Laboratories to hold board meeting

Colinz Laboratories will hold a meeting of the Board of Directors of the Company on 31 July 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Colinz Laboratories standalone net profit rises 11.11% in the December 2022 quarter

1 year agoBusiness Standard

Colinz Laboratories standalone net profit rises 200.00% in the December 2021 quarter

2 years agoBusiness Standard

Colinz Laboratories standalone net profit rises 66.67% in the September 2021 quarter

3 years agoBusiness Standard